Reaction
Sudden Hearing Loss reporting signals
As of the last recalculation, Sudden Hearing Loss appears in 1,985 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-FKJP (PRR 13.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Fkjp | 58 | 13.5 | 13.5 |
| Adalimumab-Aaty | 59 | 13.4 | 13.5 |
| Adalimumab-Adaz | 59 | 12.1 | 12.1 |
| Romiplostim | 12 | 8.4 | 8.4 |
| Agalsidase Beta | 7 | 8.0 | 8.0 |
| Tadalafil | 54 | 5.8 | 5.8 |
| Guanfacine | 4 | 5.3 | 5.3 |
| Inclisiran | 4 | 5.2 | 5.2 |
| Daratumumab | 17 | 4.5 | 4.5 |
| Ledipasvir And Sofosbuvir | 8 | 4.4 | 4.4 |
| Ranibizumab | 11 | 4.4 | 4.4 |
| Drospirenone And Ethinyl Estradiol | 16 | 3.8 | 3.8 |
| Siponimod | 3 | 3.5 | 3.5 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 2.9 | 2.9 |
| Aflibercept | 8 | 2.7 | 2.7 |
| Galcanezumab-Gnlm | 5 | 1.7 | 1.7 |